Home  »  Hot Stocks   »  Is a Correction Looming Ahead for Brainstorm Cell ...

Is a Correction Looming Ahead for Brainstorm Cell Therapeutics Inc. (BCLI)

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -9.74% from its latest closing price compared to the recent 1-year high of $4.70. The company’s stock price has collected 4.76% of gains in the last five trading sessions.

Is It Worth Investing in Brainstorm Cell Therapeutics Inc. (NASDAQ :BCLI) Right Now?

Plus, the 36-month beta value for BCLI is at -0.34. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Brainstorm Cell Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The average price from analysts is $13.00, which is $5.24 above the current price. BCLI currently public float of 28.31M and currently shorts hold a 9.50% ratio of that float. Today, the average trading volume of BCLI was 272.63K shares.

BCLI’s Market Performance

BCLI stocks went up by 4.76% for the week, with a monthly drop of -50.35% and a quarterly performance of -55.56%, while its annual performance rate touched -40.74%. The volatility ratio for the week stands at 14.80% while the volatility levels for the past 30 days are set at 13.47% for Brainstorm Cell Therapeutics Inc. The simple moving average for the period of the last 20 days is -32.12% for BCLI stocks with a simple moving average of -44.31% for the last 200 days.

Analysts’ Opinion of BCLI

Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04th of the previous year 2021.

Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.

BCLI Trading at -47.56% from the 50-Day Moving Average

After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.55% of loss for the given period.

Volatility was left at 13.47%, however, over the last 30 days, the volatility rate increased by 14.80%, as shares sank -50.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.00% lower at present.

During the last 5 trading sessions, BCLI rose by +4.76%, which changed the moving average for the period of 200-days by -44.83% in comparison to the 20-day moving average, which settled at $2.5040. In addition, Brainstorm Cell Therapeutics Inc. saw -56.00% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for BCLI

Equity return is now at value -236.40, with -116.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.69.